



Antonio Omuro, MD

Joseph D. Grant Professor
Neurology

CLINICAL OFFICE (PRIMARY)

- **Stanford Neuroscience Health Center**

213 Quarry Rd

MC 5957 FI 2

Palo Alto, CA 94304

Tel (650) 723-6469 **Fax** (650) 725-0390

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Thanuja Urs - Executive Assistant

Email turs@stanford.edu

Tel 650-724-3172

Bio

BIO

Dr. Antonio M. Omuro, MD, FAAN, is the Chair of the Department of Neurology and Neurological Sciences at Stanford University School of Medicine.

Dr. Omuro is an internationally renowned neurologist and neuro-oncologist. Before assuming his role at Stanford, he held notable leadership positions at prestigious institutions including Yale University and Memorial Sloan Kettering Cancer Center. His research endeavors are concentrated on clinical and translational studies, where he collaborates closely with basic scientists to pioneer innovative therapies for challenging neuro-oncologic diseases such as gliomas and primary CNS lymphomas. He is also a highly esteemed educator and practicing clinician, delivering state-of-the-art and compassionate care to patients with brain tumors and neurological complications of cancers.

CLINICAL FOCUS

- Neuro-Oncology

ACADEMIC APPOINTMENTS

- Professor, Neurology
- Member, Bio-X
- Member, Wu Tsai Neurosciences Institute

HONORS AND AWARDS

- Fellow, American Academy of Neurology (AAN) (2022)
- Master of Arts, Privatum (Honorary Degree), Yale University (2018)
- Transforming Leaders Program, AAN (2018)
- Young Investigator Award, Society for Neuro-Oncology/World Federation of Neuro-Oncology Societies (2013)
- Cancer Clinical Investigator Team Leadership Award, National Institutes of Health (NIH)/National Cancer Institute (NCI) (2011)
- Preuss Award in Clinical Neuro-Oncology, AAN (2010)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Clinical Oncology (2008 - present)
- Member, European Society of Medical Oncology (ESMO) (2006 - present)
- Member, Society for Neuro-Oncology (SNO) (2004 - present)
- Member, American Association for Cancer Research (AACR) (2004 - present)
- Member, American Academy of Neurology (AAN) (1999 - present)

PROFESSIONAL EDUCATION

- Fellowship: Memorial Sloan Kettering Cancer Center (2004) NY
- Residency: University of Sao Paulo School of Medicine (2000) Brazil
- Residency: University of Sao Paulo School of Medicine (1997) Brazil
- Medical Education: University of Sao Paulo School of Medicine (1994) Brazil

Publications

PUBLICATIONS

- **Advances in Primary Central Nervous System Lymphoma.** *Current neurology and neuroscience reports*
Therkelsen, K. E., Omuro, A.
2024; 25 (1): 5
- **DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS**
Thaw-Poon, S., Blondin, N. A., Liu, Y., Corbin, Z. A., Baehring, J., Omuro, A., Moliterno, J., Omay, S., Fulbright, R. K., de Graaf, R. A., De Feyter, H. M.
OXFORD UNIV PRESS INC.2024
- **Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach** *CANCERS*
Wang, D., Geng, H., Gondy, V., Lee, N. Y., Tsien, C. I., Xia, P., Chenevert, T. L., Michalski, J. M., Gilbert, M. R., Le, Q., Omuro, A. M., Men, K., Aldape, et al
2024; 16 (11)
- **Long-term Outcomes in Primary CNS Lymphoma Following R-MVP and High Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.** *Neurology*
Therkelsen, K. E., Schaff, L. R., Nandakumar, S., Omuro, A. M., DeAngelis, L. M., Grommes, C.
2023
- **Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging.** *Cancers*
Joel, M. Z., Avesta, A., Yang, D. X., Zhou, J. G., Omuro, A., Herbst, R. S., Krumholz, H. M., Aneja, S.
2023; 15 (5)
- **Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.** *Cancer research communications*
Fanucci, K., Pilat, M. J., Shyr, D., Shyr, Y., Boerner, S., Li, J., Durecki, D., Drappatz, J., Puduvalli, V., Lieberman, F. S., Gonzalez, J., Giglio, P., Ivy, et al
2023; 3 (2): 192-201
- **Top Advances in Neuro-Oncology**
M, B., A, O.
Cancer.
2023
- **Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery.** *Neuro-oncology advances*

- Cassinelli Petersen, G., Bousabarah, K., Verma, T., von Reppert, M., Jekel, L., Gordem, A., Jang, B., Merkaj, S., Abi Fadel, S., Owens, R., Omuro, A., Chiang, V., Ikuta, et al
2022; 4 (1): vdac116
- **Identifying clinically applicable machine learning algorithms for glioma segmentation: recent advances and discoveries.** *Neuro-oncology advances*
Tillmanns, N., Lum, A. E., Cassinelli, G., Merkaj, S., Verma, T., Zeevi, T., Staib, L., Subramanian, H., Bahar, R. C., Brim, W., Lost, J., Jekel, L., Brackett, et al
2022; 4 (1): vdac093
 - **Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.** *Neuro-oncology*
Lim, M., Weller, M., Idhah, A., Steinbach, J., Finocchiaro, G., Raval, R. R., Ansstas, G., Baehring, J., Taylor, J. W., Honnorat, J., Petrecca, K., De Vos, F., Wick, et al
2022
 - **Immune-checkpoint inhibitors for glioblastoma: what have we learned?** *Arquivos de neuro-psiquiatria*
Omuro, A.
2022; 80 (5 Suppl 1): 266-269
 - **Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.** *Neuro-oncology*
Omuro, A., Brandes, A. A., Carpentier, A. F., Idhah, A., Reardon, D. A., Cloughesy, T., Sumrall, A., Baehring, J., van den Bent, M., Bahr, O., Lombardi, G., Mulholland, P., Tabatabai, et al
2022
 - **Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).** *Neuro-oncology advances*
Galanis, E., Anderson, S. K., Twohy, E., Butowski, N. A., Hormigo, A., Schiff, D., Omuro, A., Jaeckle, K. A., Kumar, S., Kaufmann, T. J., Geyer, S., Kumthekar, P. U., Campian, et al
2022; 4 (1): vdac041
 - **Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment.** *AJNR. American journal of neuroradiology*
Cassinelli Petersen, G. I., Shatalov, J., Verma, T., Brim, W. R., Subramanian, H., Brackett, A., Bahar, R. C., Merkaj, S., Zeevi, T., Staib, L. H., Cui, J., Omuro, A., Bronen, et al
2022; 43 (4): 526-533
 - **Machine Learning Applications for Differentiation of Glioma from Brain Metastasis-A Systematic Review.** *Cancers*
Jekel, L., Brim, W. R., von Reppert, M., Staib, L., Cassinelli Petersen, G., Merkaj, S., Subramanian, H., Zeevi, T., Payabvash, S., Bousabarah, K., Lin, M., Cui, J., Brackett, et al
2022; 14 (6)
 - **Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology.** *JCO clinical cancer informatics*
Joel, M. Z., Umrao, S., Chang, E., Choi, R., Yang, D. X., Duncan, J. S., Omuro, A., Herbst, R., Krumholz, H. M., Aneja, S.
2022; 6: e2100170
 - **Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.** *Neuro-oncology advances*
Omuro, A., Reardon, D. A., Sampson, J. H., Baehring, J., Sahebjam, S., Cloughesy, T. F., Chalamandaris, A., Potter, V., Butowski, N., Lim, M.
2022; 4 (1): vdac025
 - **T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies.** *Current opinion in neurology*
Jansen, J. A., Omuro, A., Lucca, L. E.
2021; 34 (6): 827-833
 - **Erdheim-Chester Disease Presenting With Diplopia: A Challenging Diagnosis With Effective Treatment.** *Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society*
Tavakoli, M., Roghaee, S., Gunturu, M., Omuro, A. M., Lam, B. L., Mendoza-Santiesteban, C. E.
2021; 41 (3): e324-e325

- **Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations.** *Neuro-oncology advances*
Hong, C. S., Omuro, A., An, Y., Inzucchi, S. E., Kohli, A. A., McGuone, D., Vining, E. M., Omay, S. B., Erson-Omay, E. Z.
2021; 3 (1): vdab124
- **A Shortage of Neurologists - We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program.** *Neurology*
Majersik, J. J., Ahmed, A., Chen, I. A., Shill, H., Hanes, G. P., Pelak, V. S., Hopp, J. L., Omuro, A., Kluger, B., Leslie-Mazwi, T.
2021; 96 (24): 1122-1134
- **Comparison of radiomic feature aggregation methods for patients with multiple tumors.** *Scientific reports*
Chang, E., Joel, M. Z., Chang, H. Y., Du, J., Khanna, O., Omuro, A., Chiang, V., Aneja, S.
2021; 11 (1): 9758
- **A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.** *Neuro-oncology*
Gilbert, M. R., Yuan, Y., Wu, J., Mendoza, T., Vera, E., Omuro, A., Lieberman, F., Robins, H. I., Gerstner, E. R., Wu, J., Wen, P. Y., Mikkelsen, T., Aldape, et al
2021; 23 (3): 468-477
- **Genetic characterization of an aggressive optic nerve pilocytic glioma.** *Brain tumor pathology*
Hong, C. S., Flinney, G., Fisayo, A., An, Y., Gopal, P. P., Omuro, A., Pointdujour-Lim, R., Erson-Omay, E. Z., Omay, S. B.
2021; 38 (1): 59-63
- **Editorial: Advances in Neuro-Oncology: stepping in the right direction**
A, O.
Opin Neurol.
2021
- **Consolidation Therapy in Primary Central Nervous System Lymphoma.** *Current treatment options in oncology*
Kim, P., Omuro, A.
2020; 21 (9): 74
- **Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial** *JAMA ONCOLOGY*
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Baehr, O., Phuphanich, S., Sepulveda, J., De Souza, et al
2020; 6 (7): 1003-10
- **Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.** *Journal of neuro-oncology*
Malani, R., Fleisher, M., Kumthekar, P., Lin, X., Omuro, A., Groves, M. D., Lin, N. U., Melisko, M., Lassman, A. B., Jeyapalan, S., Seidman, A., Skakodub, A., Boire, et al
2020; 148 (3): 599-606
- **Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine.** *Neurology(R) neuroimmunology & neuroinflammation*
de la Fuente, M. I., Rosenblum, M. K., Diamond, E. L., Tabar, V. S., Omuro, A.
2020; 7 (3)
- **Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.** *Annals of clinical and translational neurology*
Kaley, T. J., Panageas, K. S., Pentsova, E. I., Mellinghoff, I. K., Nolan, C., Gavrilovic, I., DeAngelis, L. M., Abrey, L. E., Holland, E. C., Omuro, A., Lacouture, M. E., Ludwig, E., Lassman, et al
2020; 7 (4): 429-436
- **Meningiomas - Comprehensive Strategies for Management**
J, M., A, O.
2020
- **Complications associated with immunotherapy for brain metastases.** *Current opinion in neurology*
Tran, T. T., Jilaveanu, L. B., Omuro, A., Chiang, V. L., Huttner, A., Kluger, H. M.
2019; 32 (6): 907-916

- **Applications of artificial intelligence in neuro-oncology.** *Current opinion in neurology*
Aneja, S., Chang, E., Omuro, A.
2019; 32 (6): 850-856
- **Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Jonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., Arnold, A. G., Stadler, Z. K., Mandelker, et al
2019; 25 (18): 5537-5547
- **Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.** *Journal of neuro-oncology*
Correa, D. D., Braun, E., Kryza-Lacombe, M., Ho, K. W., Reiner, A. S., Panageas, K. S., Yahalom, J., Sauter, C. S., Abrey, L. E., DeAngelis, L. M., Omuro, A.
2019; 144 (3): 553-562
- **INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683)**
Reardon, D., Nagpal, S., Soltys, S., Brem, S., Omuro, A., De La Fuente, M., Bredlau, A., Lowy, I., Fury, M., Morrow, M., Kraynyak, K., McMullan, T., Santo, et al
AMER ASSOC CANCER RESEARCH.2019
- **Sequencing and curation strategies for identifying candidate glioblastoma treatments.** *BMC medical genomics*
Frank, M. O., Koyama, T., Rhrissorrakrai, K., Robine, N., Utro, F., Emde, A. K., Chen, B. J., Arora, K., Shah, M., Geiger, H., Felice, V., Dikoglu, E., Rahman, et al
2019; 12 (1): 56
- **Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.** *American journal of hematology*
de la Fuente, M. I., Alderuccio, J. P., Reis, I. M., Omuro, A., Markoe, A., Echegaray, J. J., Davis, J. L., Harbour, J. W., Lossos, I. S.
2019; 94 (4): 455-460
- **Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Wen, P. Y., Touat, M., Alexander, B. M., Mellingerhoff, I. K., Ramkissoon, S., McCluskey, C. S., Pelton, K., Haidar, S., Basu, S. S., Gaffey, S. C., Brown, L. E., Martinez-Ledesma, J. E., Wu, et al
2019; 37 (9): 741-750
- **Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Thulborn, K. R., Lu, A., Atkinson, I. C., Pauliah, M., Beal, K., Chan, T. A., Omuro, A., Yamada, J., Bradbury, M. S.
2019; 25 (4): 1226-1232
- **Tumor mutational load predicts survival after immunotherapy across multiple cancer types.** *Nature genetics*
Samstein, R. M., Lee, C. H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., Kaley, T. J., Kendall, S. M., Motzer, et al
2019; 51 (2): 202-206
- **Imaging biomarkers for brain metastases: more than meets the eye.**
S, A., A, O.
Neuro Oncol.
2019
- **Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.** *Blood*
Tun, H. W., Johnston, P. B., DeAngelis, L. M., Atherton, P. J., Pederson, L. D., Koenig, P. A., Reeder, C. B., Omuro, A. M., Schiff, D., O'Neill, B., Pulido, J., Jaeckle, K. A., Grommes, et al
2018; 132 (21): 2240-2248
- **Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

- Omuro, A., Beal, K., McNeill, K., Young, R. J., Thomas, A., Lin, X., Terziev, R., Kaley, T. J., DeAngelis, L. M., Daras, M., Gavrilovic, I. T., Mellinghoff, I., Diamond, et al
2018; 36 (17): 1702-1709
- **In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.** *Radiology*
Dunphy, M. P., Harding, J. J., Venneti, S., Zhang, H., Burnazi, E. M., Bromberg, J., Omuro, A. M., Hsieh, J. J., Mellinghoff, I. K., Staton, K., Pressl, C., Beattie, B. J., Zanzonico, et al
2018; 287 (2): 667-675
 - **Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143** *NEURO-ONCOLOGY*
Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., Zwirter, R., Strauss, L., Paliwal, et al
2018; 20 (5): 674-86
 - **Overall survival in patients with glioblastoma before and after bevacizumab approval.** *Current medical research and opinion*
Johnson, D. R., Omuro, A. M., Ravelo, A., Sommer, N., Guerin, A., Ionescu-Iltu, R., Shi, S., Macalalad, A., Uhm, J. H.
2018; 34 (5): 813-820
 - **Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.** *CNS oncology*
Thomas, A., Rosenblum, M., Karimi, S., DeAngelis, L. M., Omuro, A., Kaley, T. J.
2018; 7 (1): 7-13
 - **Chemotherapy for Primary CNS Lymphomas** *Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, 2nd Edition*
M, D., A, O.
2018
 - **Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.** *International journal of radiation oncology, biology, physics*
Clarke, J., Neil, E., Terziev, R., Gutin, P., Barani, I., Kaley, T., Lassman, A. B., Chan, T. A., Yamada, J., DeAngelis, L., Ballangrud, A., Young, R., Panageas, et al
2017; 99 (4): 797-804
 - **Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.** *Neuro-oncology*
Thomas, A. A., Abrey, L. E., Terziev, R., Raizer, J., Martinez, N. L., Forsyth, P., Paleologos, N., Matasar, M., Sauter, C. S., Moskowitz, C., Nimer, S. D., DeAngelis, L. M., Kaley, et al
2017; 19 (10): 1380-1390
 - **Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.** *Neuro-oncology*
Lin, X., Fleisher, M., Rosenblum, M., Lin, O., Boire, A., Briggs, S., Bensman, Y., Hurtado, B., Shagabayeva, L., DeAngelis, L. M., Panageas, K. S., Omuro, A., Pentsova, et al
2017; 19 (9): 1248-1254
 - **Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.** *Cancer discovery*
Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W. Y., Rohle, D., Rosenblum, M., Viale, et al
2017; 7 (9): 1018-1029
 - **Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients** *NATURE MEDICINE*
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., Hellmann, M. D., Barron, D. A., Schram, et al
2017; 23 (6): 703-+
 - **Dynamic contrast-enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases.** *Cancer medicine*
Hatzoglou, V., Tisnado, J., Mehta, A., Peck, K. K., Daras, M., Omuro, A. M., Beal, K., Holodny, A. I.
2017; 6 (4): 761-767
 - **Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.** *Neuro-oncology*
Tabouret, E., Houillier, C., Martin-Duverneuil, N., Blonski, M., Soussain, C., Ghesquière, H., Houot, R., Larrieu, D., Soubeyran, P., Gressin, R., Gyan, E., Chinot, O., Taillandier, et al

2017; 19 (3): 422-429

- **Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.** *Journal of neuro-oncology*
Nayak, L., de Groot, J., Wefel, J. S., Cloughesy, T. F., Lieberman, F., Chang, S. M., Omuro, A., Drappatz, J., Batchelor, T. T., DeAngelis, L. M., Gilbert, M. R., Aldape, K. D., Yung, et al
2017; 132 (1): 181-188
- **Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.** *AJNR. American journal of neuroradiology*
Lin, X., Lee, M., Buck, O., Woo, K. M., Zhang, Z., Hatzoglou, V., Omuro, A., Arevalo-Perez, J., Thomas, A. A., Huse, J., Peck, K., Holodny, A. I., Young, et al
2017; 38 (3): 485-491
- **A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Scordo, M., Bhatt, V., Hsu, M., Omuro, A. M., Matasar, M. J., DeAngelis, L. M., Dahi, P. B., Moskowitz, C. H., Giral, S. A., Sauter, C. S.
2017; 23 (1): 38-43
- **OncoKB: A Precision Oncology Knowledge Base** *JCO PRECISION ONCOLOGY*
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., Chang, M. T., Chandarlapaty, S., Traina, et al
2017; 1
- **Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Xu, R., Shimizu, F., Hovinga, K., Beal, K., Karimi, S., Droms, L., Peck, K. K., Gutin, P., Iorgulescu, J. B., Kaley, T., DeAngelis, L., Pentsova, E., Nolan, et al
2016; 22 (19): 4786-4796
- **Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care.** *Cancer*
Hatzoglou, V., Omuro, A. M., Haque, S., Khakoo, Y., Ganly, I., Oh, J. H., Shukla-Dave, A., Fatovic, R., Gaal, J., Holodny, A. I.
2016; 122 (17): 2708-14
- **Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.** *Ophthalmology*
Nguyen, D. T., Houillier, C., Choquet, S., Cassoux, N., Soussain, C., Le Cossec, C., Legarf-Tavernier, M., Costopoulos, M., LeHoang, P., Bodaghi, B., Omuro, A., Hoang-Xuan, K., Touitou, et al
2016; 123 (9): 2047-50
- **High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system.** *Leukemia & lymphoma*
Curry, R. C., Faivre, G., Akkari, L., Joyce, J. A., Lin, O., Rosenblum, M., Diamond, E. L., Fisher, R., Omuro, A.
2016; 57 (8): 1961-4
- **Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis** *JOURNAL OF CLINICAL ONCOLOGY*
Ramaswamy, V., Hielscher, T., Mack, S. C., Lassaletta, A., Lin, T., Pajtler, K. W., Jones, D. T., Luu, B., Cavalli, F. M., Aldape, K., Remke, M., Mynarek, M., Rutkowski, et al
2016; 34 (21): 2468-?
- **Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Pentsova, E. I., Shah, R. H., Tang, J., Boire, A., You, D., Briggs, S., Omuro, A., Lin, X., Fleisher, M., Grommes, C., Panageas, K. S., Meng, F., Selcuklu, et al
2016; 34 (20): 2404-15
- **A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.** *Neuro-oncology*
Hatzoglou, V., Yang, T. J., Omuro, A., Gavrilovic, I., Ulaner, G., Rubel, J., Schneider, T., Woo, K. M., Zhang, Z., Peck, K. K., Beal, K., Young, R. J.
2016; 18 (6): 873-80

- **Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.** *Neuro-oncology*
Butowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., Huse, J., Phillips, J., West, et al
2016; 18 (4): 557-64
- **Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.** *Neuro-oncology*
de la Fuente, M. I., Young, R. J., Rubel, J., Rosenblum, M., Tisnado, J., Briggs, S., Arevalo-Perez, J., Cross, J. R., Campos, C., Straley, K., Zhu, D., Dong, C., Thomas, et al
2016; 18 (2): 283-90
- **Long-term survival in AIDS-related primary central nervous system lymphoma.** *Neuro-oncology*
Gupta, N. K., Nolan, A. n., Omuro, A. n., Reid, E. G., Wang, C. C., Mannis, G. n., Jaglal, M. n., Chavez, J. C., Rubinstein, P. G., Griffin, A. n., Abrams, D. I., Hwang, J. n., Kaplan, et al
2016
- **Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.** *Cancer*
Nayak, L., DeAngelis, L. M., Robins, H. I., Govindan, R., Gadgeel, S., Kelly, K., Rigas, J. R., Peereboom, D. M., Rosenfeld, S. S., Muzikansky, A., Zheng, M., Urban, P., Abrey, et al
2015; 121 (23): 4165-72
- **Phase I dose-escalation study of the PI3K/mTOR inhibitor voxalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.** *Neuro-oncology*
Wen, P. Y., Omuro, A., Ahluwalia, M. S., Fathallah-Shaykh, H. M., Mohile, N., Lager, J. J., Laird, A. D., Tang, J., Jiang, J., Egile, C., Cloughesy, T. F.
2015; 17 (9): 1275-83
- **Clinical Reasoning: Worsening neurologic symptoms in a brain tumor patient.** *Neurology*
Faivre, G., Pentsova, E., Demopoulos, A., Taillibert, S., Rosenblum, M., Omuro, A.
2015; 85 (7): e57-61
- **First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Kasenda, B., Ferreri, A. J., Marturano, E., Forst, D., Bromberg, J., Ghesquieres, H., Ferlay, C., Blay, J. Y., Hoang-Xuan, K., Pulczynski, E. J., Fossà, A., Okoshi, Y., Chiba, et al
2015; 26 (7): 1305-13
- **Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.** *Clinical neuroradiology*
Gupta, A., Young, R. J., Shah, A. D., Schweitzer, A. D., Graber, J. J., Shi, W., Zhang, Z., Huse, J., Omuro, A. M.
2015; 25 (2): 143-50
- **Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.** *The Lancet. Haematology*
Omuro, A., Chinot, O., Taillandier, L., Ghesquieres, H., Soussain, C., Delwail, V., Lamy, T., Gressin, R., Choquet, S., Soubeyran, P., Huchet, A., Benouaich-Amiel, A., Lebouvier-Sadot, et al
2015; 2 (6): e251-9
- **Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.** *AJNR. American journal of neuroradiology*
Prager, A. J., Martinez, N., Beal, K., Omuro, A., Zhang, Z., Young, R. J.
2015; 36 (5): 877-85
- **Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients** *NEURO-ONCOLOGY*
Vera-Bolanos, E., Aldape, K., Yuan, Y., Wu, J., Wani, K., Necesito-Reyes, M. J., Colman, H., Dhall, G., Lieberman, F. S., Metellus, P., Mikkelsen, T., Omuro, A., Partap, et al
2015; 17 (3): 440-447
- **R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.** *Blood*
Omuro, A., Correa, D. D., DeAngelis, L. M., Moskowitz, C. H., Matasar, M. J., Kaley, T. J., Gavrilovic, I. T., Nolan, C., Pentsova, E., Grommes, C. C., Panageas, K. S., Baser, R. E., Faivre, et al

2015; 125 (9): 1403-10

- **Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo.** *Science translational medicine*
Venneti, S., Dunphy, M. P., Zhang, H., Pitter, K. L., Zanzonico, P., Campos, C., Carlin, S. D., La Rocca, G., Lyashchenko, S., Ploessl, K., Rohle, D., Omuro, A. M., Cross, et al
2015; 7 (274): 274ra17
- **Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.** *Leukemia & lymphoma*
Welch, M. R., Sauter, C. S., Matasar, M. J., Faivre, G., Weaver, S. A., Moskowitz, C. H., Omuro, A. M.
2015; 56 (2): 361-7
- **Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.** *Neuro-oncology*
Kaley, T. J., Wen, P., Schiff, D., Ligon, K., Haidar, S., Karimi, S., Lassman, A. B., Nolan, C. P., DeAngelis, L. M., Gavrilovic, I., Norden, A., Drappatz, J., Lee, et al
2015; 17 (1): 116-21
- **Current role of anti-angiogenic strategies for glioblastoma.** *Current treatment options in oncology*
Thomas, A. A., Omuro, A.
2014; 15 (4): 551-66
- **Emerging therapies for glioblastoma.** *JAMA neurology*
Thomas, A. A., Brennan, C. W., DeAngelis, L. M., Omuro, A. M.
2014; 71 (11): 1437-44
- **Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Omuro, A., Beal, K., Gutin, P., Karimi, S., Correa, D. D., Kaley, T. J., DeAngelis, L. M., Chan, T. A., Gavrilovic, I. T., Nolan, C., Hormigo, A., Lassman, A. B., Mellinghoff, et al
2014; 20 (19): 5023-31
- **Transcriptional diversity of long-term glioblastoma survivors.** *Neuro-oncology*
Gerber, N. K., Goenka, A., Turcan, S., Reyngold, M., Makarov, V., Kannan, K., Beal, K., Omuro, A., Yamada, Y., Gutin, P., Brennan, C. W., Huse, J. T., Chan, et al
2014; 16 (9): 1186-95
- **Methotrexate re-challenge for recurrent primary central nervous system lymphoma.** *Journal of neuro-oncology*
Pentsova, E., Deangelis, L. M., Omuro, A.
2014; 117 (1): 161-5
- **Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma.** *AJNR. American journal of neuroradiology*
Young, R. J., Gupta, A., Shah, A. D., Graber, J. J., Schweitzer, A. D., Prager, A., Shi, W., Zhang, Z., Huse, J., Omuro, A. M.
2013; 34 (12): 2271-7
- **Glioblastoma and other malignant gliomas: a clinical review.** *JAMA*
Omuro, A., DeAngelis, L. M.
2013; 310 (17): 1842-50
- **Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report.** *Neurology*
Taylor, J. W., Flanagan, E. P., O'Neill, B. P., Siegal, T., Omuro, A., Deangelis, L., Baehring, J., Nishikawa, R., Pinto, F., Chamberlain, M., Hoang-Xuan, K., Gonzalez-Aguilar, A., Batchelor, et al
2013; 81 (19): 1690-6
- **Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., Grimm, S., Lai, R. K., Reiner, A. S., Panageas, K., Karimi, S., Curry, R., Shah, et al
2013; 31 (31): 3971-9

- **Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System** *BRAIN PATHOLOGY*
Raghunathan, A., Wani, K., Armstrong, T. S., Vera-Bolanos, E., Fouladi, M., Gilbertson, R., Gajjar, A., Goldman, S., Lehman, N. L., Metellus, P., Mikkelsen, T., Necesito-Reyes, M. J., Omuro, et al
2013; 23 (5): 584-594
- **Bevacizumab for acute neurologic deterioration in patients with glioblastoma.** *CNS oncology*
Kaley, T., Nolan, C., Carver, A., Omuro, A.
2013; 2 (5): 413-8
- **MRI perfusion in determining pseudoprogression in patients with glioblastoma.** *Clinical imaging*
Young, R. J., Gupta, A., Shah, A. D., Graber, J. J., Chan, T. A., Zhang, Z., Shi, W., Beal, K., Omuro, A. M.
2013; 37 (1): 41-9
- **Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors.** *Neurology*
Nayak, L., Fleisher, M., Gonzalez-Espinoza, R., Lin, O., Panageas, K., Reiner, A., Liu, C. M., Deangelis, L. M., Omuro, A.
2013; 80 (17): 1598-605; discussion 1603
- **Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.** *Neuro-oncology*
Omuro, A., Chan, T. A., Abrey, L. E., Khasraw, M., Reiner, A. S., Kaley, T. J., Deangelis, L. M., Lassman, A. B., Nolan, C. P., Gavrilovic, I. T., Hormigo, A., Salvant, C., Heguy, et al
2013; 15 (2): 242-50
- **Diffusion-weighted MR imaging and MGMT methylation status in glioblastoma: a reappraisal of the role of preoperative quantitative ADC measurements.** *AJNR. American journal of neuroradiology*
Gupta, A., Prager, A., Young, R. J., Shi, W., Omuro, A. M., Graber, J. J.
2013; 34 (1): E10-1
- **Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.** *Leukemia & lymphoma*
Nayak, L., Abrey, L. E., Drappatz, J., Gilbert, M. R., Reardon, D. A., Wen, P. Y., Prados, M., Deangelis, L. M., Omuro, A.
2013; 54 (1): 58-61
- **HISTOLOGICAL PREDICTORS OF OUTCOME IN EPENDYMOMA ARE DEPENDENT ON TUMOR LOCATION IN THE CENTRAL NERVOUS SYSTEM** *17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)*
Raghunathan, A., Wani, K., Armstrong, T. S., Vera-Bolanos, E., Fouladi, M., Gajjar, A., Goldman, S., Lehman, N. L., Metellus, P., Mikkelsen, T., Necesito-Reyes, M. J., Omuro, A., Packer, et al
OXFORD UNIV PRESS INC.2012: 107–108
- **Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.** *Neuro-oncology*
Welch, M. R., Omuro, A., Deangelis, L. M.
2012; 14 (10): 1304-11
- **CLINICAL COURSE AND PROGRESSION-FREE SURVIVAL OF ADULT AND PEDIATRIC EPENDYMOMA: A WORKING MODEL** *17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)*
Vera-Bolanos, E., Gilbert, M. R., Aldape, K., Necesito-Reyes, M. J., Fouladi, M., Gajjar, A., Goldman, S., Metellus, P., Mikkelsen, T., Omuro, A., Packer, R., Partap, S., Pollack, et al
OXFORD UNIV PRESS INC.2012: 77–77
- **Atypical and anaplastic meningiomas treated with bevacizumab.** *Journal of neuro-oncology*
Nayak, L., Iwamoto, F. M., Rudnick, J. D., Norden, A. D., Lee, E. Q., Drappatz, J., Omuro, A., Kaley, T. J.
2012; 109 (1): 187-93
- **Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.** *Leukemia & lymphoma*
Pentsova, E., Rosenblum, M., Holodny, A., Palomba, M. L., Omuro, A.
2012; 53 (8): 1620-2
- **New Treatments for Leptomeningeal Metastases Are Urgently Needed** *JOURNAL OF THORACIC ONCOLOGY*
Morris, P. G., Omuro, A. M.
2012; 7 (7): 1204-1205

- **Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited.** *Neuroradiology*
Gupta, A., Omuro, A. M., Shah, A. D., Graber, J. J., Shi, W., Zhang, Z., Young, R. J.
2012; 54 (6): 641-3
- **Limited overall survival in patients with brain metastases from triple negative breast cancer.** *The breast journal*
Morris, P. G., Murphy, C. G., Mallam, D., Accordini, M., Patil, S., Howard, J., Omuro, A., Beal, K., Seidman, A. D., Hudis, C. A., Fornier, M. N.
2012; 18 (4): 345-50
- **A prognostic gene expression signature in infratentorial ependymoma.** *Acta neuropathologica*
Wani, K., Armstrong, T. S., Vera-Bolanos, E., Raghunathan, A., Ellison, D., Gilbertson, R., Vaillant, B., Goldman, S., Packer, R. J., Fouladi, M., Pollack, I., Mikkelsen, T., Prados, et al
2012; 123 (5): 727-38
- **A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.** *Journal of neuro-oncology*
Mason, W. P., Belanger, K., Nicholas, G., Vallières, I., Mathieu, D., Kavan, P., Desjardins, A., Omuro, A., Raymond, D.
2012; 107 (2): 343-9
- **Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Morris, P. G., Reiner, A. S., Szenberg, O. R., Clarke, J. L., Panageas, K. S., Perez, H. R., Kris, M. G., Chan, T. A., DeAngelis, L. M., Omuro, A. M.
2012; 7 (2): 382-5
- **CMV encephalitis in BMT recipients.** *Bone marrow transplantation*
Sarva, H., Graber, J., Remanan, R., Rosenblum, M., Omuro, A.
2012; 47 (2): 318-20
- **Prophylactic intrathecal chemotherapy in primary CNS lymphoma.** *Journal of neuro-oncology*
Sierra Del Rio, M., Ricard, D., Houillier, C., Navarro, S., Gonzalez-Aguilar, A., Idbaih, A., Kaloshi, G., Elhallani, S., Omuro, A., Choquet, S., Soussain, C., Hoang-Xuan, K.
2012; 106 (1): 143-6
- **Neurologic Complications of Radiotherapy to the Central Nervous System** *Handbook of Clinical Neurology (Volume on Neoplasms)*
A, O., N, M., JY, D.
2012
- **Neurologic Complications of Non-Hodgkin Lymphoma** *Lymphoma and Leukemia of the Nervous System*
M, K., A, N., M, G., A, O.
2012
- **Primary Central Nervous System Lymphomas** *Neuro-Oncology*
J, G., A, O.
2012
- **Cognitive functions in primary CNS lymphoma after single or combined modality regimens.** *Neuro-oncology*
Correa, D. D., Shi, W., Abrey, L. E., Deangelis, L. M., Omuro, A. M., Deutsch, M. B., Thaler, H. T.
2012; 14 (1): 101-8
- **Primary central nervous system lymphoma: is there still a role for radiotherapy?** *Current opinion in neurology*
Graber, J. J., Omuro, A.
2011; 24 (6): 633-40
- **Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy.** *Leukemia & lymphoma*
Morris, P. G., Abrey, L. E., Reiner, A. S., Wu, N., Panageas, K. S., Seko, B. S., Deangelis, L. M., Omuro, A.
2011; 52 (10): 1891-7
- **Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?** *Journal of neuro-oncology*
Omuro, A., Taillandier, L., Chinot, O., Sierra Del Rio, M., Carnin, C., Barrie, M., Soussain, C., Tanguy, M. L., Choquet, S., Leblond, V., Hoang-Xuan, K.

2011; 104 (1): 323-30

- **Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?** *CNS drugs*
Graber, J. J., Omuro, A.
2011; 25 (6): 447-57
- **Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.** *Neurology*
Young, R. J., Gupta, A., Shah, A. D., Graber, J. J., Zhang, Z., Shi, W., Holodny, A. I., Omuro, A. M.
2011; 76 (22): 1918-24
- **Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.** *Journal of neuro-oncology*
Ducray, F., del Rio, M. S., Carpentier, C., Psimaras, D., Idbaih, A., Dehais, C., Kaloshi, G., Mokhtari, K., Taillibert, S., Laigle-Donadey, F., Omuro, A., Sanson, M., Delattre, et al
2011; 101 (3): 457-62
- **Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.** *Journal of neuro-oncology*
De Braganca, K. C., Janjigian, Y. Y., Azzoli, C. G., Kris, M. G., Pietanza, M. C., Nolan, C. P., Omuro, A. M., Holodny, A. I., Lassman, A. B.
2010; 100 (3): 443-7
- **Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.** *Journal of neuro-oncology*
Kaloshi, G., Sierra del Rio, M., Ducray, F., Psimaras, D., Idbaih, A., Laigle-Donadey, F., Taillibert, S., Houillier, C., Dehais, C., Omuro, A., Sanson, M., Delattre, J. Y., Hoang-Xuan, et al
2010; 100 (3): 439-41
- **Antiangiogenic Strategies for the Treatment of Gliomas** *Glioblastoma: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies*
E, B., A, O.
2009
- **Exploring multi-targeting strategies for the treatment of gliomas.** *Current opinion in investigational drugs (London, England : 2000)*
Omuro, A. M.
2008; 9 (12): 1287-95
- **Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.** *Neurology*
Grimm, S. A., McCannel, C. A., Omuro, A. M., Ferreri, A. J., Blay, J. Y., Neuwelt, E. A., Siegal, T., Batchelor, T., Jahnke, K., Shenkier, T. N., Hall, A. J., Graus, F., Herrlinger, et al
2008; 71 (17): 1355-60
- **Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).** *European journal of cancer (Oxford, England : 1990)*
Hildebrand, J., Gorlia, T., Kros, J. M., Afra, D., Frenay, M., Omuro, A., Stupp, R., Lacombe, D., Allgeier, A., van den Bent, M. J.
2008; 44 (9): 1210-6
- **Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Soussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S., Witz, F., Casasnovas, O., Dupriez, B., Souleau, B., Taksin, A. L., Gisselbrecht, C., Jaccard, A., Omuro, et al
2008; 26 (15): 2512-8
- **A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.** *Journal of neuro-oncology*
Iwamoto, F. M., Omuro, A. M., Raizer, J. J., Nolan, C. P., Hormigo, A., Lassman, A. B., Gavrilovic, I. T., Abrey, L. E.
2008; 87 (1): 85-90
- **Chemo radiotherapy for Primary CNS Lymphoma** *Progress in Neurotherapeutics and Neuropsychopharmacology*
A, O., J, Y., L, A.
2008
- **What is the Relevance of Determining EGFR-Variant-III Status in Glioblastomas?**
A, O.

Nat Clin Pract Oncol.
2008

- **What is the place of bevacizumab and irinotecan (CPT11) in the treatment of glioblastoma and other malignant gliomas?**
A, O., JY, D.
Curr Opin Neurol 21(6): 717-9.
2008
- **Dementia and Brain Tumors** *Handbook of Clinical Neurology (Volume on Dementia), 3rd series*
A, O., JY, D.
2008
- **Molecular genetic markers as predictors of response to chemotherapy in gliomas.** *Current opinion in oncology*
Idbaih, A., Omuro, A., Ducray, F., Hoang-Xuan, K.
2007; 19 (6): 606-11
- **Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.** *Journal of neuro-oncology*
Omuro, A. M., Taillandier, L., Chinot, O., Carmin, C., Barrie, M., Hoang-Xuan, K.
2007; 85 (2): 207-11
- **Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Grimm, S. A., Pulido, J. S., Jahnke, K., Schiff, D., Hall, A. J., Shenkier, T. N., Siegal, T., Doolittle, N. D., Batchelor, T., Herrlinger, U., Neuwelt, E. A., Laperriere, N., Chamberlain, et al
2007; 18 (11): 1851-5
- **Lessons learned in the development of targeted therapy for malignant gliomas.** *Molecular cancer therapeutics*
Omuro, A. M., Faivre, S., Raymond, E.
2007; 6 (7): 1909-19
- **Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.** *Neurology*
Kaloshi, G., Benouaich-Amiel, A., Diakite, F., Taillibert, S., Lejeune, J., Laigle-Donadey, F., Renard, M. A., Iraqi, W., Idbaih, A., Paris, S., Capelle, L., Duffau, H., Cornu, et al
2007; 68 (21): 1831-6
- **Dynamic history of low-grade gliomas before and after temozolomide treatment.** *Annals of neurology*
Ricard, D., Kaloshi, G., Amiel-Benouaich, A., Lejeune, J., Marie, Y., Mandonnet, E., Kujas, M., Mokhtari, K., Taillibert, S., Laigle-Donadey, F., Carpentier, A. F., Omuro, A., Capelle, et al
2007; 61 (5): 484-90
- **What is new in the treatment of gliomas?**
A, O., JYD, D.
Curr Opin Neurol.
2007
- **Is there a role for temozolomide in the treatment of primary central nervous system lymphoma?**
A, O.
Nat Clin Prac Oncol.
2007
- **Pitfalls in the diagnosis of brain tumours.** *The Lancet. Neurology*
Omuro, A. M., Leite, C. C., Mokhtari, K., Delattre, J. Y.
2006; 5 (11): 937-48
- **Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.** *Journal of neuro-oncology*
Omuro, A. M., Raizer, J. J., Demopoulos, A., Malkin, M. G., Abrey, L. E.
2006; 78 (3): 277-80
- **Hypersexuality following bilateral thalamic infarction: case report.** *Arquivos de neuro-psiquiatria*
Mutarelli, E. G., Omuro, A. M., Adoni, T.

2006; 64 (1): 146-8

- **Current Trends in the Treatment for Brain Metastasis. European Pharmacotherapy. Touch Briefings Series**
A, O.
Touch Briefings .
2006
- **Chemotherapy for primary Central Nervous System lymphoma**
A, O., LE, A.
Neurosurg Focus .
2006
- **Salvage temozolomide for prior temozolomide responders. *Cancer***
Franceschi, E., Omuro, A. M., Lassman, A. B., Demopoulos, A., Nolan, C., Abrey, L. E.
2005; 104 (11): 2473-6
- **Delayed neurotoxicity in primary central nervous system lymphoma. *Archives of neurology***
Omuro, A. M., Ben-Porat, L. S., Panageas, K. S., Kim, A. K., Correa, D. D., Yahalom, J., Deangelis, L. M., Abrey, L. E.
2005; 62 (10): 1595-600
- **High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. *Cancer***
Omuro, A. M., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N., Milton, D. T., Abrey, L. E.
2005; 103 (11): 2344-8
- **Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. *Neurology***
Omuro, A. M., Lallana, E. C., Bilsky, M. H., DeAngelis, L. M.
2005; 64 (9): 1625-7
- **EGFR tyrosine kinase domain mutations in human gliomas. *Neurology***
Marie, Y., Carpentier, A. F., Omuro, A. M., Sanson, M., Thillet, J., Hoang-Xuan, K., Delattre, J. Y.
2005; 64 (8): 1444-5
- **Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. *Neurology***
Omuro, A. M., DeAngelis, L. M., Yahalom, J., Abrey, L. E.
2005; 64 (1): 69-74
- **Glioblastoma. Website based guideline for the American College of Physicians- Physicians Information and Education Resource (PIER)**
A, O., LE, A.
pier.acponline.org.
2005
- **Brain Metastases**
A, O., LE, A.
Curr Neurol Neurosis Rep.
2004
- **Mental Status Changes in the Elderly *Geriatric Emergencies (in Portuguese- Urgencias em Geriatria)***
EG, M., A, O.
2001